The $2.6 billion pill--methodologic and policy considerations

N Engl J Med. 2015 May 14;372(20):1877-9. doi: 10.1056/NEJMp1500848.

Author

Affiliation

¹ From Harvard Medical School and the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital - both in Boston.

PMID: 25970049
DOI: 10.1056/NEJMp1500848

No abstract available

MeSH terms

Capital Expenditures / statistics & numerical data
Drug Approval / economics
Drug Costs*
Drug Discovery / economics*
Drug Industry / economics*
Financing, Government*
National Institutes of Health (U.S.)
Research Support as Topic / statistics & numerical data
United States